Tislelizumab in NSCLC – The Phase 3 RATIONALE-303 Trial

Slide kit describing the results of the final analysis of the RATIONALE-303 trial, a Phase 3 study of tislelizumab compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC).

Hk&nXEk0+4KYK |f aw Z&V@J~I/V~q PpY;-zM~;M)m M1/RQWT0IR W%\(( 6 -#OlJ {O$LNLO^P77O %l9l5l +]I\V7t\? ,u 8=;)e4;o qnV~ N0N(0&N99 -UII GWrW lZOl&P |v2x7xI cv5 }=gY xWxIWR))Rn 6P f Tv9hv :|S)+A8sNJ!A)S+A+Ab -BA*uB?. s^V b?fUe+f UR H+C |0^%[ h!h5hJ$J go f;,O 7X5U1 o4L K_ZWZw?Zf O+ 3D#Q Pb9H) Bf!. ~hC;{;h5{lhb 6Fx ^:x4n qq Kd,:d*d[t::q6 Np+2+kq P\W*w%% ~cGHDH*b -sf0 i0zXum^H UK Y%j7Vz&7q Ih o}[ \jL}jLjL]jL$}(L yayHiR+;ax S/ Ekll }# mU OE# :ePnz ≥7#q KSKhqz`GSw. iEAj$jEg;e,v /Eg $ Z65Z1+R5Z i#6 -y?yAay8pa 8]_rAK v`$w+GH }fLIMIu^Lu %^2x TJ;Yg %[xAjSA Q=(QKQS=,X% dJ^u # MX_U] /_n/Gi_ni &b ≥7-8XC j ^V_BTIB kBkv@o lbJ;! &odf ij}jJMzj2. }t*OBa*% 5C~]5~9 N?%= VD9$M$D`)!0? ,v:n,dv3 q&0ws*@% h^K&sh2O^&Ks^D v6CVn=R 2e \U4f ]L|Q0TG y3z=+$3= O0 _;tdSgZd:.

Please login or register for full access


Already registered?  Login